Harvard-linked Sana Biotechnology will raise as much as $397m if it floats at the upper end and underwriters take up the greenshoe option.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The autoimmune disease drug developer's series A round has closed at $42.4m after Roche Venture Fund added funding to a first close co-led by AbbVie Ventures.

SR One reinvested in a series B round for the degenerative disorder drug developer that was led by venture fund Logos Capital.

GV and Novartis Venture Fund joined 6 Dimensions Capital in a round that brought Harvard’s oncology drug developer's overall funding to $160m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The firm, which specialises in commercialising public and corporate research, has closed its largest fund to date.

The mental health benefits platform, which counts Providence Health and Services as an investor, doubled its valuation to $2.3m in the series E round.

Main Street Advisors has invested $9m in the plant-based formula provider through a round already backed by Kaiser Permanente Ventures.

Harvard-founded Nuvalent lured funding from Deerfield to debut with two assets devoted to overcoming kinase-driven resistance to non-small cell lung cancer.